YBX1 and metabolic dysfunction-associated steatotic liver disease: In addition, the hepatocyte-specific knockout of YBX1 reduced lipid accumulation and improved liver steatosis in the MASLD mouse model, implying that YBX1 is involved in the progression of MASLD.